Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method
Research output: Journal contributions › Journal articles › Research › peer-review
Authors
Parallel administration of the proton pump inhibitor (PPI) esomeprazole has been shown to decrease oral bioavailability of posaconazole in healthy volunteers. We prospectively analyzed serum samples (n = 59) obtained from hematology patients (n = 27) under posaconazole prophylaxis. Patients treated concomitantly with pantoprazole had significantly lower posaconazole levels than patients without PPI treatment (median levels of 630 μg/liter versus 1,125 μg/liter, respectively). These results suggest that drug monitoring is relevant when posaconazole and pantoprazole are administered concomitantly. Copyright © 2010, American Society for Microbiology. All Rights Reserved.
| Original language | English |
|---|---|
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 54 |
| Issue number | 9 |
| Pages (from-to) | 4029-4032 |
| Number of pages | 4 |
| DOIs | |
| Publication status | Published - 09.2010 |
| Externally published | Yes |
- Pharmacology
- Infectious Diseases
- Pharmacology (medical)
ASJC Scopus Subject Areas
- SDG 3 - Good Health and Well-being
Sustainable Development Goals
- Chemistry - Adult, Aged, Antifungal Agents, Chromatography, High Pressure Liquid, Female, Hematologic Neoplasms, Humans, Male, Middle Aged, Mycoses, Prospective Studies, Triazoles